Evidence map›Paper›PMID 24872518›Full record

ArticleClinical and vaccine immunology : CVI2014

Chemically modified peptides based on the membrane-proximal external region of the HIV-1 envelope induce high-titer, epitope-specific nonneutralizing antibodies in rabbits.

Vincent J Venditto, Lindsay Wieczorek, Sebastian Molnar, Fernando Teque, Gary Landucci, Douglas S Watson, Donald Forthal, Victoria R Polonis, Jay A Levy, Francis C Szoka

Open access · diamondAbstract read
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Vincent J VendittoDepartments of Bioengineering and Therapeutic Sciences, School of Pharmacy, University of California, San Francisco, San Francisco, California, USA.
Lindsay WieczorekLaboratory of Vaccine Immunology, Walter Reed Army Institute of Research, Military HIV Research Program, Silver Spring, Maryland, USA The Henry M. Jackson Foundation, Bethesda, Maryland, USA.
Sebastian MolnarLaboratory of Vaccine Immunology, Walter Reed Army Institute of Research, Military HIV Research Program, Silver Spring, Maryland, USA The Henry M. Jackson Foundation, Bethesda, Maryland, USA.
Fernando TequeDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Gary LanducciDivision of Infectious Diseases, Department of Medicine, University of California, Irvine, Irvine, California, USA.
Douglas S WatsonDepartments of Bioengineering and Therapeutic Sciences, School of Pharmacy, University of California, San Francisco, San Francisco, California, USA.
Donald ForthalDivision of Infectious Diseases, Department of Medicine, University of California, Irvine, Irvine, California, USA.
Victoria R PolonisLaboratory of Vaccine Immunology, Walter Reed Army Institute of Research, Military HIV Research Program, Silver Spring, Maryland, USA.
Jay A LevyDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Francis C SzokaDepartments of Bioengineering and Therapeutic Sciences, School of Pharmacy, University of California, San Francisco, San Francisco, California, USA szoka@cgl.ucsf.edu.
University of California, San Francisco · USHenry M. Jackson Foundation · USUniversity of California, Irvine · USWalter Reed Army Institute of Research · US

Funding

Targeted Drug Delivery to Surface Receptors.R01GM061851 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SZOKA, FRANCIS C. · 2001 to 2015
$3.5M
HIV neutralizing antibodies induced by chemically modified MPR epitopesR21AI093135 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SZOKA, FRANCIS C. · 2011 to 2012
$425k
Do peptide mimetics of gp41 improve antibody-epitope interactions?F32AI095062 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VENDITTO, VINCENT JOSEPH · 2012 to 2014
$163k
NIAID NIH HHS F32 AI095062NIAID NIH HHS F32AI095062NIAID NIH HHS R21 AI093135NIGMS NIH HHS R01 GM061851
6 · The paper itself

Abstract

Broadly neutralizing monoclonal antibodies (bNAbs) 2F5 and 4E10 bind to the membrane proximal external region (MPER) of gp41 and also cross-react with phospholipids. In this study, we investigated if chemical modifications on the MPER adjacent to 2F5 and 4E10 epitopes using mimetics of inflammation-associated posttranslational modifications to induce 2F5- and 4E10-like bNAbs can break tolerance. We synthesized a series of chemically modified peptides spanning the MPER. The serine, threonine, and tyrosine residues in the peptides were modified with sulfate, phosphate, or nitrate moieties and presented in liposomes for rabbit immunizations. All immunizations resulted in high antisera titers directed toward both the modified and unmodified immunogens. Tyrosine modification was observed to significantly suppress antiepitope responses. Sera with strong anti-gp140 titers were purified by affinity chromatography toward the MPER peptide and found to possess a higher affinity toward the MPER than did the bNAbs 2F5 and 4E10. Modest neutralization was observed in the H9 neutralization assay, but neutralization was not observed in the TZM-bl cell or peripheral blood mononuclear cell (PBMC) neutralization assay platforms. Although neutralizing antibodies were not induced by this approach, we conclude that chemical modifications can increase the immune responses to poorly immunogenic antigens, suggesting that chemical modification in an appropriate immunization protocol should be explored further as an HIV-1 vaccine strategy.

Indexed as

AIDS VaccinesAnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibody AffinityBroadly Neutralizing AntibodiesCell LineChromatography, AffinityCross Reactionsenv Gene Products, Human Immunodeficiency VirusEpitopesHIV-1HIV AntibodiesHIV Envelope Protein gp41Neutralization TestsRabbits2F5 monoclonal antibodyAIDS VaccinesAntibodies, MonoclonalAntibodies, NeutralizingBroadly Neutralizing Antibodiesenv Gene Products, Human Immunodeficiency VirusEpitopesgp140 envelope protein, Human immunodeficiency virus 1HIV AntibodiesHIV Envelope Protein gp41

Identifiers

PMID24872518
PMCPMC4135905
OpenAlexW2097766975

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.